Phibro Animal Health (NASDAQ:PAHC) Issues FY 2025 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 1.340-1.480 for the period, compared to the consensus EPS estimate of 1.550. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.2 billion.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PAHC. Bank of America raised their price objective on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price target on the stock. Three research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $15.00.

Phibro Animal Health Stock Performance

Shares of PAHC traded up $0.35 during mid-day trading on Friday, hitting $23.85. The company’s stock had a trading volume of 203,227 shares, compared to its average volume of 158,175. Phibro Animal Health has a one year low of $9.40 and a one year high of $25.11. The stock’s 50-day moving average is $22.37 and its two-hundred day moving average is $19.38. The firm has a market capitalization of $966.00 million, a PE ratio of 55.47, a price-to-earnings-growth ratio of 0.57 and a beta of 0.51. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.64 and a current ratio of 2.94.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.44%. The company had revenue of $273.16 million for the quarter, compared to analyst estimates of $262.44 million. As a group, sell-side analysts anticipate that Phibro Animal Health will post 1.57 EPS for the current year.

Phibro Animal Health Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th will be paid a dividend of $0.12 per share. The ex-dividend date is Wednesday, November 27th. This represents a $0.48 annualized dividend and a yield of 2.01%. Phibro Animal Health’s dividend payout ratio is 111.63%.

Insiders Place Their Bets

In other Phibro Animal Health news, Director E Thomas Corcoran purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, September 4th. The shares were purchased at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the completion of the purchase, the director now directly owns 25,000 shares of the company’s stock, valued at approximately $500,500. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 50.07% of the company’s stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.